Literature DB >> 8100834

Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance.

M Castro Cabezas1, T W de Bruin, H W de Valk, C C Shoulders, H Jansen, D Willem Erkelens.   

Abstract

To establish whether insulin resistance and/or postprandial fatty acid metabolism might contribute to familial combined hyperlipidemia (FCH) we have examined parameters of insulin resistance and lipid metabolism in six FCH kindreds. Probands and relatives (n = 56) were divided into three tertiles on the basis of fasting plasma triglycerides (TG). Individuals in the highest tertile (TG > 2.5 mM; n = 14) were older and had increased body mass index, systolic blood pressure, and fasting plasma insulin concentrations compared with individuals in the lowest tertile (n = 24). The former also presented with decreased HDL cholesterol and increased total plasma cholesterol, HDL-TG, and apoprotein B, E, and CIII concentrations. Insulin concentrations were positively correlated with plasma apo B, apo CIII, apo E, and TG, and inversely with HDL cholesterol. Fasting nonesterified fatty acids (NEFA) were elevated in FCH subjects compared to six unrelated controls and five subjects with familial hypertriglyceridemia. Prolonged and exaggerated postprandial plasma NEFA concentrations were found in five hypertriglyceridemic FCH probands. In FCH the X2 minor allele of the AI-CIII-AIV gene cluster was associated with increased fasting plasma TG, apo CIII, apo AI, and NEFA concentrations and decreased postheparin lipolytic activities. The clustering of risk factors associated with insulin resistance in FCH indicates a common metabolic basis for the FCH phenotype and the syndrome of insulin resistance probably mediated by an impaired fatty acid metabolism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100834      PMCID: PMC293556          DOI: 10.1172/JCI116544

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Concordance for dyslipidemic hypertension in male twins.

Authors:  J V Selby; B Newman; J Quiroga; J C Christian; M A Austin; R R Fabsitz
Journal:  JAMA       Date:  1991-04-24       Impact factor: 56.272

2.  Familial combined hyperlipidaemia linked to the apolipoprotein AI-CII-AIV gene cluster on chromosome 11q23-q24.

Authors:  A P Wojciechowski; M Farrall; P Cullen; T M Wilson; J D Bayliss; B Farren; B A Griffin; M J Caslake; C J Packard; J Shepherd
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

3.  Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities.

Authors:  G F Lewis; N M O'Meara; P A Soltys; J D Blackman; P H Iverius; W L Pugh; G S Getz; K S Polonsky
Journal:  J Clin Endocrinol Metab       Date:  1991-04       Impact factor: 5.958

Review 4.  Further insights into the pathophysiology of hyperapobetalipoproteinemia: role of basic proteins I, II, III.

Authors:  P O Kwiterovich; M Motevalli; M Miller; P S Bachorik; S D Kafonek; S Chatterjee; T Beaty; D Virgil
Journal:  Clin Chem       Date:  1991-03       Impact factor: 8.327

5.  Insulin inhibits apolipoprotein B secretion in isolated human hepatocytes.

Authors:  A I Salhanick; S I Schwartz; J M Amatruda
Journal:  Metabolism       Date:  1991-03       Impact factor: 8.694

6.  Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.

Authors:  M C Cabezas; T W de Bruin; L A Kock; W Kortlandt; M Van Linde-Sibenius Trip; H Jansen; D W Erkelens
Journal:  Metabolism       Date:  1993-04       Impact factor: 8.694

7.  Proteolysis of human apolipoprotein B: effect on quantitative immunoturbidimetry.

Authors:  T W De Bruin; M C Vos; W Kortlandt; B N Bouma; D W Erkelens
Journal:  Clin Chim Acta       Date:  1990-12-14       Impact factor: 3.786

8.  Postprandial decrease in HDL cholesterol and HDL apo A-I in normal subjects in relation to triglyceride metabolism.

Authors:  T W De Bruin; C B Brouwer; J A Gimpel; D W Erkelens
Journal:  Am J Physiol       Date:  1991-03

9.  Genetic evidence from 7 families that the apolipoprotein B gene is not involved in familial combined hyperlipidemia.

Authors:  G Rauh; H Schuster; B Müller; S Schewe; C Keller; G Wolfram; N Zöllner
Journal:  Atherosclerosis       Date:  1990-07       Impact factor: 5.162

10.  Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge.

Authors:  K M Cianflone; Z Yasruel; M A Rodriguez; D Vas; A D Sniderman
Journal:  J Lipid Res       Date:  1990-11       Impact factor: 5.922

View more
  18 in total

Review 1.  Nonesterified fatty acids in blood pressure control and cardiovascular complications.

Authors:  B M Egan; E L Greene; T L Goodfriend
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

2.  Combined analysis of genome scans of dutch and finnish families reveals a susceptibility locus for high-density lipoprotein cholesterol on chromosome 16q.

Authors:  Päivi Pajukanta; Hooman Allayee; Kelly L Krass; Ali Kuraishy; Aino Soro; Heidi E Lilja; Rebecca Mar; Marja-Riitta Taskinen; Ilpo Nuotio; Markku Laakso; Jerome I Rotter; Tjerk W A de Bruin; Rita M Cantor; Aldons J Lusis; Leena Peltonen
Journal:  Am J Hum Genet       Date:  2003-03-12       Impact factor: 11.025

Review 3.  Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

Authors:  Jacqueline de Graaf; Mario J Veerkamp; Anton F H Stalenhoef
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

4.  Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels.

Authors:  P Pajukanta; J D Terwilliger; M Perola; T Hiekkalinna; I Nuotio; P Ellonen; M Parkkonen; J Hartiala; K Ylitalo; J Pihlajamäki; K Porkka; M Laakso; J Viikari; C Ehnholm; M R Taskinen; L Peltonen
Journal:  Am J Hum Genet       Date:  1999-05       Impact factor: 11.025

5.  Ethnicity differences in plasma apoC-III levels between African American and Caucasian youths.

Authors:  Ji-Young Lee; Hye-Ryun Hong; Hyun-Sik Kang
Journal:  World J Pediatr       Date:  2011-05-15       Impact factor: 2.764

Review 6.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Authors:  Sung Hee Choi; Henry N Ginsberg
Journal:  Trends Endocrinol Metab       Date:  2011-05-26       Impact factor: 12.015

7.  Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

Authors:  Thomas M van Himbergen; Seiko Otokozawa; Nirupa R Matthan; Ernst J Schaefer; Aaron Buchsbaum; Masumi Ai; Lambertus J H van Tits; Jacqueline de Graaf; Anton F H Stalenhoef
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-10-15       Impact factor: 8.311

8.  Association of stearoyl-CoA desaturase 1 activity with familial combined hyperlipidemia.

Authors:  Rebecca Mar-Heyming; Makoto Miyazaki; Daphna Weissglas-Volkov; Nicholas A Kolaitis; Narimaan Sadaat; Christopher Plaisier; Päivi Pajukanta; Rita M Cantor; Tjerk W A de Bruin; James M Ntambi; Aldons J Lusis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-03-13       Impact factor: 8.311

Review 9.  Insulin resistance and the sympathetic nervous system.

Authors:  Brent M Egan
Journal:  Curr Hypertens Rep       Date:  2003-06       Impact factor: 5.369

10.  Families with familial combined hyperlipidemia and families enriched for coronary artery disease share genetic determinants for the atherogenic lipoprotein phenotype.

Authors:  H Allayee; B E Aouizerat; R M Cantor; G M Dallinga-Thie; R M Krauss; C D Lanning; J I Rotter; A J Lusis; T W de Bruin
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.